Netherlands· NL-d51f980fac4e
Imcivree 10 mg/ml oplossing voor injectie
A setmelanotide product containing setmelanotideacetaat, registered in Netherlands by Rhythm Pharmaceuticals Netherlands B.V.. The same ATC class is registered in 12 of our 19 countries.
Checked against CBG-MEB (Netherlands) on
Informational only — not a medical device.
Where it is registered
Setmelanotide is registered in 12 of 19 countries.
Countries holding a registration under ATC A08AA12 (setmelanotide), each read from that country’s own register.
- This record: Netherlands, from CBG-MEB (Netherlands)
- 8 of them publish a price we can compare per daily dose
Setmelanotide · ATC A08AA12
12 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Franceprice
- Icelandprice
- Netherlands
- Polandprice
- Switzerlandprice
- United Kingdom
- United Statesprice
The record
At a glance
CBG-MEB (Netherlands)- Active substance
- SETMELANOTIDEACETAAT
- Manufacturer
- Rhythm Pharmaceuticals Netherlands B.V.
- Country
- Netherlands (NL)
- ATC code
- A08AA12
- ATC class
- Setmelanotide
- Defined daily dose
- 1.5 mg, P
- Reimbursed
- Not published by this register
- Source register
- CBG-MEB (Netherlands)
- Last checked
- September 29, 2026
Packs & prices · 1
- cbg_meb_idEU/1/21/1564
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Setmelanotide in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- FranceIMCIVREE 10 mg/ml, solution injectableRHYTHM PHARMACEUTICALS NETHERLANDS (PAYS-BAS)
- IrelandIMCIVREE 10 mg/ml solution for injectionRhythm Pharmaceuticals Netherlands B.V
- IcelandIMCIVREERhythm Pharmaceuticals Netherlands B.V
- CzechiaIMCIVREERhythm Pharmaceuticals Netherlands B.V., Amsterdam
- SwitzerlandIMCIVREE 10 mg/ml, InjektionslösungRhythm Pharmaceuticals Switzerland GmbH
- SpainIMCIVREE 10 MG/ML SOLUCION INYECTABLERhythm Pharmaceuticals Netherlands B.V.
- FinlandImcivreeRhythm Pharmaceuticals Netherlands B.V.
- United KingdomImcivree 10mg/1ml solution for injection vialsRhythm Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Imcivree
- Liechtenstein · Imcivree
- Norway · Imcivree
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/5cac5fd5-d3c6-461e-a0e5-f4de9e7a9f85 GET /v1/drugs/5cac5fd5-d3c6-461e-a0e5-f4de9e7a9f85?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Oplossing voor injectie",
"route": "Subcutaan gebruik",
"soort": null,
"source": "cbg_meb",
"smpc_url": "https://www.ema.europa.eu/en/documents/product-information/imcivree-epar-product-information_nl.pdf",
"strength": null,
"atc_label": "Setmelanotide",
"detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp126987",
"excipients": [
"BENZYLALCOHOL (E 1519)",
"CARMELLOSE NATRIUM (E 466)",
"DINATRIUMEDETAAT 2-WATER",
"FENOL",
"MANNITOL (D-) (E 421)",
"N-(CARBONYL-METHOXYPOLYETHYLEENGLYCOL 2000)-1,2-DISTEAROYL-SN-GLYCERO-3-PHOSPHOETHANOLAMINE NATRIUM",
"NATRIUMHYDROXIDE (E 524)",
"STIKSTOF (HEAD SPACE) (E 941)",
"WATER VOOR INJECTIE",
"ZOUTZUUR (E 507)"
],
"substances": [
"SETMELANOTIDEACETAAT"
],
"leaflet_url": null,
"authorised_at": "2021/07/16",
"procedure_number": "EMEA/H/C/005089",
"dispensing_status": "Uitsluitend recept",
"registration_number": "EU/1/21/1564",
"additional_monitoring": "N"
}See everything about setmelanotide.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.